Share your experience with Eosinophilic Gastroenteritis (EGE), Eosinophilic Gastritis (EG) and Eosinophilic Colitis (EC)
IQVIA is a global research firm commissioned to conduct interviews with patients who have been diagnosed with Eosinophilic Gastroenteritis (EGE), Eosinophilic Gastritis (EG) and Eosinophilic Colitis (EC) (moving forward in this document, EGE, EG, and EC will be referred and Eosinophilic Gastrointestinal Diseases (EGID)). IQVIA is seeking patients to participate in a confidential one-on-one phone interview to share their experiences with EGIDs. As an EGID patient, you are potentially eligible for this research study.Purpose
The purpose of the study is to explore patients' experiences with EGIDs. Specifically, the study will focus on understanding patients' symptoms and the impact of these symptoms on patients' daily life. The outputs of this research study will help the sponsor, a pharmaceutical company, understand what outcomes are most relevant to patients in order to inform the development of new treatments for EGIDs.Your Involvement
If you are interested, you will be asked to participate in a 60-90 minutes telephone interview with an IQVIA healthcare researcher. At no point before, during, or after the interview will you be contacted to purchase anything or be asked to take any medication. No personal identifying information will be included in the study documents and summary reports generated from this research study. In return for your voluntary participation in the interview, your time and effort will be compensated with a $150 gift card or check that you will receive after completion of the phone interview.Next Steps
If you are interested in participating in this research study, please indicate below. You will then be asked several screening questions to confirm your eligibility. You will also have the opportunity to provide consent to participate. Afterward, IQVIA will contact you to schedule and conduct your interview. With any questions, please contact Julie Bailey at JBailey@imscg.com or 1 917 602 6634.